
ABOUT RYBODYN

WHO WE ARE
RyboDyn is a pioneering immunotherapy developer on a mission to transform the way we approach human health. By unlocking the secrets of the dark proteome, we’re redefining patient care with breakthrough therapies that target previously hidden markers of disease. Our innovative approach—powered by our proprietary RyboCypher™ technology—sets us apart as leaders in the field of next-generation immunotherapies.

OUR MISSION
To transform hidden biology into actionable insights and deliver first-in-class immunotherapies that revolutionize patient care.

OUR STORY
At RyboDyn, our journey began with a simple yet powerful question: What if the mysteries hidden within our genetic code could be the key to life-saving treatments? We set out to explore the uncharted territories of the dark genome and dark proteome—vast realms that conventional methods overlook. Through relentless research and innovation, we discovered unique Dark Targets™ that form the foundation of our breakthrough immunotherapies.
RYBODYN TEAM

-
IMAD AJJAWI, PHD, MBA
Co-Founder & Chief Executive Officer
-
COREY DAMBACHER, PHD
Founder, President, & Chief Technology Officer
-
KERRY WILSON, PHD
Co-Founder & VP, Platform Development
-
ASHLEY WOODFIN, MSC
Co-Founder & Bioinformatics Lead - Target Discovery
-
ANDY BASS
VP, Marketing & Communications
-
MARCO BLANCHETTE, PHD
VP, Target Discovery
-
JOEL CHICK, PHD
VP, Proteomics Discovery
-
LEO GARNAR-WORTZEL, PHD
Scientist
-
ARIEL SCHWARTZ, PHD
VP, AI
-
JESSICA WEIR
Senior Associate Scientist
ADVISORY TEAM

-
GORDON B. MILLS, MD, PHD
Clinical & Scientific Advisor
-
NEEHA ZAIDI, MD
Clinical & Scientific Advisor
-
TODD PETERSON, PHD
Life Science Business Advisor
-
RICHARD KURTZ, PHD
Life Science Business Advisor
-
ALEX JAEGER, PHD
Academic Co-Founder, Scientific Advisor
-
JOSÉ MORACHIS, PHD
Investor, Scientific Advisor
-
WILL ALAYNICK, PHD
Investor, Scientific Advisor

OUR INVESTORS *
OUR PARTNERS *
OUR INVESTORS * OUR PARTNERS *
